TP53 and neoplasm: In accordance with primary tumour material, none of the baseline blood samples revealed any TP53 mutations, whilst upon MDM2-inhibitor treatment, multiple TP53 were detected in cfDNA, suggesting emergence of TP53 mutant clones resistant to MDM2 inhibition [68].